MRI-monitored long-term therapeutic hydrogel system for brain tumors without surgical resection.

[1]  Beom Suk Lee,et al.  Long-term theranostic hydrogel system for solid tumors. , 2012, Biomaterials.

[2]  M. Nishio,et al.  Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer , 2011, British Journal of Cancer.

[3]  A. Huang,et al.  Possibilities of new therapeutic strategies in brain tumors. , 2010, Cancer treatment reviews.

[4]  T. Mikkelsen,et al.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  N. Ravi,et al.  In situ formation of hydrogels as vitreous substitutes: Viscoelastic comparison to porcine vitreous. , 2008, Journal of biomedical materials research. Part A.

[6]  D. Brat,et al.  Phase I analysis of BCNU-impregnated biodegradable polymer wafers followed by systemic interferon alfa-2b in adults with recurrent glioblastoma multiforme , 2008, Journal of Neuro-Oncology.

[7]  M. McGirt,et al.  Use of Gliadel (BCNU) Wafer in the Surgical Treatment of Malignant Glioma: A 10-Year Institutional Experience , 2008, Annals of Surgical Oncology.

[8]  Steven H. Lin,et al.  Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies , 2008, Expert review of anticancer therapy.

[9]  R. Warnick,et al.  Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme. , 2008, Journal of neurosurgery.

[10]  Soma Das,et al.  Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  N. Laperriere,et al.  Gliadel wafers in the treatment of malignant glioma: a systematic review , 2007, Current oncology.

[12]  J. Barcia,et al.  Fatal outcome related to carmustine implants in glioblastoma multiforme , 2007, Acta Neurochirurgica.

[13]  Raoul Kopelman,et al.  Brain cancer diagnosis and therapy with nanoplatforms. , 2006, Advanced drug delivery reviews.

[14]  H. Newton.  Handbook of Brain Tumor Chemotherapy , 2005 .

[15]  B. Lee,et al.  Synthesis and characterization of biodegradable Thermosensitive poly(organophosphazene) gels , 2004 .

[16]  Hao Zeng,et al.  Monodisperse MFe2O4 (M = Fe, Co, Mn) nanoparticles. , 2004, Journal of the American Chemical Society.

[17]  M. Taphoorn.  Neurocognitive sequelae in the treatment of low-grade gliomas. , 2003, Seminars in oncology.

[18]  B. Scheithauer,et al.  Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examination. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Xiangpeng Yuan,et al.  Current and future strategies for the treatment of malignant brain tumors. , 2003, Pharmacology & therapeutics.

[20]  R. McLendon,et al.  Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. , 2002 .

[21]  Jung-Kyo Cho,et al.  Thermosensitive/magnetic poly(organophosphazene) hydrogel as a long-term magnetic resonance contrast platform. , 2012, Biomaterials.

[22]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[23]  K. Stein,et al.  Chemotherapeutic wafers for High Grade Glioma (Review) , 2009 .

[24]  E. Goebel,et al.  Cerebral edema associated with Gliadel wafers: two case studies. , 2005, Neuro-oncology.

[25]  K. Hoang-Xuan,et al.  Recommendations for the management of adult patients with intracranial glioma ( 2002 ) , 2022 .